Myometrial disease extent on standardized morphological uterus sonographic assessment transvaginal ultrasound is associated with severe dysmenorrhea in women with adenomyosis: a prospective observational study

In: International Journal of Reproduction, Contraception, Obstetrics and Gynecology · 2026 · vol. 15(10) , pp. 3818–3822 · doi:10.18203/2320-1770.ijrcog20263411 · W7214636619
Observational OA: diamond CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-06 ⓘ

In 42 women with adenomyosis, myometrial disease extent exceeding 50% on standardized transvaginal ultrasound was strongly associated with severe dysmenorrhea.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-10-02 · read from full text ⓘ

This prospective observational study evaluated the association between standardized morphological uterus sonographic assessment features and dysmenorrhea severity in 42 premenopausal women with sonographically diagnosed adenomyosis. Researchers recorded myometrial disease extent using transvaginal ultrasound and assessed pain levels via a numerical rating scale, finding that greater disease involvement correlated with more intense symptoms. Specifically, myometrial involvement exceeding 50% was present in 56.3% of patients with severe dysmenorrhea compared to only 6.3% of those with mild symptoms, demonstrating high specificity for severe pain. The authors concluded that while standardized reporting of disease extent adds clinical value, larger studies are needed to confirm its independent predictive power. This paper is centrally about adenomyosis — specifically the correlation between sonographic disease extent and symptom severity.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: Aim was to evaluate associations between standardized morphological uterus sonographic assessment (MUSA) transvaginal ultrasound features and dysmenorrhea severity in women with adenomyosis. Methods: This prospective observational study included 42 consecutive premenopausal women with secondary dysmenorrhea and sonographically diagnosed adenomyosis between March 2025 and March 2026. Standardized transvaginal ultrasound was performed using a GE Voluson E8 system with an 8-MHz transvaginal transducer. MUSA features, disease type, and myometrial disease extent were recorded. Dysmenorrhea was assessed using a 0-10 numerical rating scale. Group comparisons and diagnostic performance measures were evaluated. Results: Participants had mild (n=16), moderate (n=10), or severe (n=16) dysmenorrhea. Heavy menstrual bleeding, dyspareunia, chronic pelvic pain, several direct MUSA features, and the presence of at least two direct MUSA features increased across symptom groups. Myometrial involvement >50% occurred in 56.3% of women with severe dysmenorrhea versus 6.3% with mild symptoms. For severe dysmenorrhea, disease extent >50% had 56.3% sensitivity, 88.5% specificity, 75.0% positive predictive value, 76.7% negative predictive value, and 76.2% accuracy. Conclusions: Greater myometrial disease extent was strongly associated with dysmenorrhea severity in this cohort. Standardized reporting of disease extent may add clinically useful information to MUSA-based ultrasound assessment, but larger patient-level studies are required to determine independent predictive value.
Full text 5,131 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Background

Aim was to evaluate associations between standardized morphological uterus sonographic assessment (MUSA) transvaginal ultrasound features and dysmenorrhea severity in women with adenomyosis.

Methods

This prospective observational study included 42 consecutive premenopausal women with secondary dysmenorrhea and sonographically diagnosed adenomyosis between March 2025 and March 2026. Standardized transvaginal ultrasound was performed using a GE Voluson E8 system with an 8-MHz transvaginal transducer. MUSA features, disease type, and myometrial disease extent were recorded. Dysmenorrhea was assessed using a 0-10 numerical rating scale. Group comparisons and diagnostic performance measures were evaluated.

Results

Participants had mild (n=16), moderate (n=10), or severe (n=16) dysmenorrhea. Heavy menstrual bleeding, dyspareunia, chronic pelvic pain, several direct MUSA features, and the presence of at least two direct MUSA features increased across symptom groups. Myometrial involvement >50% occurred in 56.3% of women with severe dysmenorrhea versus 6.3% with mild symptoms. For severe dysmenorrhea, disease extent >50% had 56.3% sensitivity, 88.5% specificity, 75.0% positive predictive value, 76.7% negative predictive value, and 76.2% accuracy.

Conclusions

Greater myometrial disease extent was strongly associated with dysmenorrhea severity in this cohort. Standardized reporting of disease extent may add clinically useful information to MUSA-based ultrasound assessment, but larger patient-level studies are required to determine independent predictive value. Metrics

References

Alcázar JL, Vara J, Usandizaga C, Ajossa S, Pascual MA, Guerriero S. Transvaginal ultrasound versus magnetic resonance imaging for diagnosing adenomyosis: a systematic review and head-to-head meta-analysis. Int J Gynaecol Obstet. 2023;161(2):397-405. DOI: https://doi.org/10.1002/ijgo.14609 Biasioli A, Degano M, Restaino S, Bagolin M, Moro F, Ciccarone F, et al. Innovative ultrasound criteria for the diagnosis of adenomyosis and correlation with symptoms: a retrospective re-evaluation. Biomedicines. 2024;12(2):463. DOI: https://doi.org/10.3390/biomedicines12020463 Bourdon M, Oliveira J, Marcellin L, Santulli P, Bordonne C, Maitrot-Mantelet L, et al. Adenomyosis of the inner and outer myometrium are associated with different clinical profiles. Hum Reprod. 2021;36(2):349-57. DOI: https://doi.org/10.1093/humrep/deaa307 Bourdon M, Santulli P, Marcellin L, Maignien C, Maitrot-Mantelet L, Bordonne C, et al. Adenomyosis: an update regarding its diagnosis and clinical features. J Gynecol Obstet Hum Reprod. 2021;50(10):102228. DOI: https://doi.org/10.1016/j.jogoh.2021.102228 Bulun SE, Yildiz S, Adli M, Wei JJ. Adenomyosis pathogenesis: insights from next-generation sequencing. Hum Reprod Update. 2021;27(6):1086-97. DOI: https://doi.org/10.1093/humupd/dmab017 Bulun SE, Yildiz S, Adli M, Chakravarti D, Parker JB, Milad M, et al. Endometriosis and adenomyosis: shared pathophysiology. Fertil Steril. 2023;119(5):746-50. DOI: https://doi.org/10.1016/j.fertnstert.2023.03.006 Schrager S, Yogendran L, Marquez CM, Sadowski EA. Adenomyosis: diagnosis and management. Am Fam Physician. 2022;105(1):33-38. Sharara FI, Kheil MH, Feki A, Rahman S, Klebanoff JS, Ayoubi JM, Moawad GN. Current and prospective treatment of adenomyosis. J Clin Med. 2021;10(15):3410. DOI: https://doi.org/10.3390/jcm10153410 Tellum T, Munro MG. Classifications of adenomyosis and correlation of phenotypes in imaging and histopathology to clinical outcomes: a review. Curr Obstet Gynecol Rep. 2022;11(1):1-11. DOI: https://doi.org/10.1007/s13669-021-00320-5 Trommelen LM, De Leeuw RA, Van den Bosch T, Huirne JAF. Grading sonographic severity of adenomyosis: a pilot study assessing feasibility and interobserver reliability. J Ultrasound Med. 2024;44(3):495-506. DOI: https://doi.org/10.1002/jum.16612 Van den Bosch T, de Bruijn AM, de Leeuw RA, Dueholm M, Exacoustos C, Valentin L, et al. Sonographic classification and reporting system for diagnosing adenomyosis. Ultrasound Obstet Gynecol. 2019;53(5):576-582. DOI: https://doi.org/10.1002/uog.19096 Yavuz O, Akdöner A, Özgözen ME, Ertan B, Kurt S, Ulukuş EC, Güney M. Prediction of adenomyosis according to revised definitions of Morphological Uterus Sonographic Assessment features. Front Med (Lausanne). 2024;11:1387515. DOI: https://doi.org/10.3389/fmed.2024.1387515 Tu F, Hellman K. Primary dysmenorrhea: diagnosis and treatment. Obstet Gynecol. 2021;137(4):752. DOI: https://doi.org/10.1097/AOG.0000000000004341 Downloads Published How to Cite Issue Section License Copyright (c) 2026 Essa M. Arafa This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (12)

Source provenance

openalex
last seen: 2026-10-16T06:01:16.192504+00:00
License: CC0 · commercial use OK